The development of stabilized recombinant HIV envelope trimers that mimic the virion
surface molecule has increased enthusiasm for a neutralizing antibody (nAb)-based HIV …

The identification of multiple broadly neutralizing antibodies (bNAbs) against the HIV-1
envelope glycoprotein (Env) trimer has facilitated its structural characterization and guided …

Generating neutralizing antibodies (nAbs) is a major goal of many current HIV-1 vaccine
efforts. To be of practical value, these nAbs must be both potent and cross-reactive in order …

Rational immunogen design aims to focus antibody responses to vulnerable sites on
primary antigens. Given the size of these antigens, there is, however, potential for eliciting …

Generating tier 2 HIV-neutralizing antibody (nAb) responses by immunization remains a
challenging problem, and the immunological barriers to induction of such responses with …

Broadly neutralizing antibodies (bNAbs) against HIV-1 develop after prolonged virus and
antibody coevolution. Previous studies showed that sequential immunization with a V3 …

Broadly neutralizing antibodies (bnAbs) targeting the trimer apex of HIV envelope are
favored candidates for vaccine design and immunotherapy because of their great …

INTRODUCTION A major goal of HIV-1 vaccine development is to identify immunogens
capable of inducing protective titers of broadly neutralizing antibodies (bNAbs) against …

The vaccine-mediated elicitation of antibodies (Abs) capable of neutralizing diverse HIV-1
strains has been a long-standing goal. To understand how broadly neutralizing antibodies …

The induction of broad and potent immunity by vaccines is the key focus of research efforts
aimed at protecting against HIV-1 infection. Soluble native-like HIV-1 envelope …